AAAAAA
Results:
1-23
|
Results: 23
Authors:
Hogan, WJ
Edwards, WD
Macon, WR
Habermann, TM
Citation: Wj. Hogan et al., Fulminant hepatic failure secondary to adenovirus following fludarabine-based chemotherapy for non-Hodgkin's lymphoma, LEUK LYMPH, 42(5), 2001, pp. 1145
Authors:
Wiernik, PH
Leong, T
Oken, MM
Neiman, RS
Habermann, TM
Bennett, JM
Schuster, S
Glick, JH
Citation: Ph. Wiernik et al., Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A long-term follow-up study of the Eastern Cooperative Oncology Group (E3481), LEUK LYMPH, 40(3-4), 2001, pp. 357-363
Authors:
Ansell, SM
Stenson, M
Habermann, TM
Jelinek, DF
Witzig, TE
Citation: Sm. Ansell et al., CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predictspatient outcome, J CL ONCOL, 19(3), 2001, pp. 720-726
Authors:
Stafford, SL
Kozelsky, TF
Garrity, JA
Kurtin, PJ
Leavitt, JA
Martenson, JA
Habermann, TM
Citation: Sl. Stafford et al., Orbital lymphoma: radiotherapy outcome and complications, RADIOTH ONC, 59(2), 2001, pp. 139-144
Authors:
Habermann, TM
Citation: Tm. Habermann, Lymphadenopathy, PRIMARY HEMATOLOGY, 2001, pp. 231-239
Authors:
Habermann, TM
Citation: Tm. Habermann, Hodgkin's disease and non-Hodgkin's lymphoma, PRIMARY HEMATOLOGY, 2001, pp. 241-253
Authors:
Habermann, TM
Citation: Tm. Habermann, Monoclonal antibody therapy for posttransplant lymphoproliferative disorders, LIVER TRANS, 6(5), 2000, pp. 657-658
Authors:
Parker, AS
Cerhan, JR
Dick, F
Kemp, J
Habermann, TM
Wallace, RB
Sellers, TA
Folsom, AR
Citation: As. Parker et al., Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women, LEUK LYMPH, 37(3-4), 2000, pp. 341-349
Authors:
Kucuk, O
Young, ML
Habermann, TM
Wolf, BC
Jimeno, J
Cassileth, PA
Citation: O. Kucuk et al., Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma - An Eastern Cooperative Oncology Group (ECOG) study, AM J CL ONC, 23(3), 2000, pp. 273-277
Authors:
Habermann, TM
Steensma, DP
Citation: Tm. Habermann et Dp. Steensma, Lymphadenopathy, MAYO CLIN P, 75(7), 2000, pp. 723-732
Authors:
Montori, VM
St Louis, EK
Habermann, TM
Citation: Vm. Montori et al., 62-year-old woman with rapidly evolving dementia, MAYO CLIN P, 75(11), 2000, pp. 1193-1196
Authors:
Fonseca, R
Inwards, DJ
Habermann, TM
Egan, KS
Citation: R. Fonseca et al., Testicular lymphoma is associated with a high risk of extranodal recurrence - Reply, CANCER, 89(3), 2000, pp. 714-714
Authors:
Fonseca, R
Habermann, TM
Colgan, JP
O'Neill, BP
White, WL
Witzig, TE
Egan, KS
Martenson, JA
Burgart, LJ
Inwards, DJ
Citation: R. Fonseca et al., Testicular lymphoma is associated with a high incidence of extranodal recurrence, CANCER, 88(1), 2000, pp. 154-161
Authors:
Loftus, EV
Tremaine, WJ
Habermann, TM
Harmsen, WS
Zinsmeister, AR
Sandborn, WJ
Citation: Ev. Loftus et al., Risk of lymphoma in inflammatory bowel disease, AM J GASTRO, 95(9), 2000, pp. 2308-2312
Authors:
Habermann, TM
Citation: Tm. Habermann, Non-Hodgkin's lymphoma: Present status and future prospects, HOSP PRACT, 34(13), 1999, pp. 81
Authors:
O'Neill, BP
Habermann, TM
Witzig, TE
Rodriguez, M
Citation: Bp. O'Neill et al., Prevention of recurrence and prolonged survival in primary central nervoussystem lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone, MED ONCOL, 16(3), 1999, pp. 211-215
Authors:
Ansell, SM
Kurtin, PJ
Stenson, M
Habermann, TM
Greipp, PR
Therneau, TM
Witzig, TE
Citation: Sm. Ansell et al., Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: Correlation with the International Index, LEUK LYMPH, 34(5-6), 1999, pp. 529-537
Authors:
Habermann, TM
Ryu, JH
Inwards, DJ
Kurtin, PJ
Citation: Tm. Habermann et al., Primary pulmonary lymphoma, SEMIN ONCOL, 26(3), 1999, pp. 307-315
Authors:
Ansell, SM
Grant, CS
Habermann, TM
Citation: Sm. Ansell et al., Primary thyroid lymphoma, SEMIN ONCOL, 26(3), 1999, pp. 316-323
Authors:
Paya, CV
Fung, JJ
Nalesnik, MA
Kieff, E
Green, M
Gores, G
Habermann, TM
Wiesner, RH
Swinnen, LJ
Woodle, ES
Bromberg, JS
Citation: Cv. Paya et al., Epstein-Barr virus-induced, posttransplant lymphoproliferative disorders, TRANSPLANT, 68(10), 1999, pp. 1517-1525
Authors:
Hanson, CA
Kurtin, PJ
Katzmann, JA
Hoyer, JD
Li, CY
Hodnefield, JM
Meyers, CH
Habermann, TM
Witzig, TE
Citation: Ca. Hanson et al., Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma, BLOOD, 94(11), 1999, pp. 3889-3896
Authors:
Gordon, LI
Young, M
Weller, E
Habermann, TM
Winter, JN
Glick, J
Ghosh, C
Flynn, P
Cassileth, PA
Citation: Li. Gordon et al., A phase II trial of 200% ProMACE-CytaBOM-in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity, BLOOD, 94(10), 1999, pp. 3307-3314
Authors:
Maguire-Boston, EK
Suman, V
Jacobsen, SJ
Moore, SB
Habermann, TM
Cerhan, JR
Folsom, AR
Citation: Ek. Maguire-boston et al., Blood transfusion and risk of non-Hodgkin's lymphoma, AM J EPIDEM, 149(12), 1999, pp. 1113-1118
Risultati:
1-23
|